Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

2(67%)

Phase Distribution

Ph not_applicable

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

N/ANon-phased studies

2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

completed133%

terminated267%

Recent Activity

0 active trials

Showing 3 of 3

terminatednot_applicable

Comparison of the Effectiveness of the Simple Puncture Compared to the Incision of an Abscess on the piLOnidal Sinus

NCT06378918

terminatednot_applicable

AR US Versus sUS or Fluoroscopic Injections for Shoulder Punction

NCT06053892

completed

Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis

NCT03416543

Clinical Trials (3)

Showing 3 of 3 trials

NCT06378918Not Applicable

Comparison of the Effectiveness of the Simple Puncture Compared to the Incision of an Abscess on the piLOnidal Sinus

Terminated

NCT06053892Not Applicable

AR US Versus sUS or Fluoroscopic Injections for Shoulder Punction

Terminated

NCT03416543

Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis

Completed

All 3 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 3